Tuesday,25 June 2024 09:11:00

Market Report by Email

If you would like to receive the daily Market Report by email please fill out your name and email address in the sign-up form below and you will be added to our mailing list.

Tuesday,25 June 2024 at 08:07

UK and European stocks opened lower following souring U.S. market sentiment at the start of the week.

Asia-Pacific markets mostly rose, while investors sold-off U.S. Big Tech stocks overnight in favour of sectors such as banking and energy.

Oil prices were little changed as worries about China’s economic recovery prospects offset supply concerns stemming from tensions in the Middle East and Ukrainian attacks on Russian refineries.

Gold prices eased, while investors looked toward key U.S. inflation data due later this week that could throw some light on the Federal Reserve’s interest rate cut stance.

In corporate news, AstraZeneca announced that a recent trial revealed that ‘Imfinzi’, or durvalumab, combined with chemotherapy, significantly enhanced event-free survival (EFS) and overall survival (OS) in patients with muscle-invasive bladder cancer (MIBC) compared to chemotherapy alone.

The pharmaceutical firm said the regimen, involving Imfinzi both before and after bladder removal surgery, was the first immunotherapy approach to successfully extend survival in bladder cancer patients.

It also confirmed that Imfinzi was well-tolerated, maintaining consistent safety profiles without increasing treatment discontinuation rates.

Markets

At 08:30

FTSE 100 8,284 +0.04%

FTSE 250 20,502 (-0.29%)

DAX 18,135 (-1.04%)

At the close

Dow Jones 39,411 +0.67%

S&P 500 5,447 (-0.31%)

NASDAQ 17,496 (-1.09%)

Fixed Income

UK 10-YR YIELD 4.064

Exchange Rates

GBP/USD 1.269

GBP/EUR 1.183

Commodities

Gold $2,325 (-0.33%)

Brent $85.02 (-0.18%)

Important - No news or research item should be construed as a recommendation to trade. The inclusion of securities within this report does not necessarily imply their suitability for individual portfolios or situations in respect of which further advice should be sought. Information contained in this report has been compiled from sources believed to be reliable but is not warranted to be accurate or complete.